154 related articles for article (PubMed ID: 38795155)
1. Janus kinase inhibitors in the treatment of pyoderma gangrenosum: case report and review.
Grisé A; Valere LC; Weinstein D; Sami N
Arch Dermatol Res; 2024 May; 316(6):238. PubMed ID: 38795155
[TBL] [Abstract][Full Text] [Related]
2. JAK inhibitors: a novel, safe, and efficacious therapy for pyoderma gangrenosum.
Castro LGM
Int J Dermatol; 2023 Aug; 62(8):1088-1093. PubMed ID: 37118975
[TBL] [Abstract][Full Text] [Related]
3. Successful use of baricitinib in the treatment of refractory rheumatoid arthritis-associated Sweet syndrome.
Nousari Y; Wu BC; Valenzuela G
Clin Exp Dermatol; 2021 Oct; 46(7):1330-1332. PubMed ID: 33914946
[No Abstract] [Full Text] [Related]
4. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
5. Repigmentation of vitiligo with oral baricitinib.
Mumford BP; Gibson A; Chong AH
Australas J Dermatol; 2020 Nov; 61(4):374-376. PubMed ID: 32491188
[No Abstract] [Full Text] [Related]
6. Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals.
Melikhov O; Kruglova T; Lytkina K; Melkonyan G; Prokhorovich E; Putsman G; Rodoman G; Vertkin A; Zagrebneva A; Stebbing J
Ann Rheum Dis; 2021 Sep; 80(9):1245-1246. PubMed ID: 34099486
[No Abstract] [Full Text] [Related]
7. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
Calabrese L; Malvaso D; Chiricozzi A; Tambone S; D'Urso DF; Guerriero C; Peris K
Expert Opin Investig Drugs; 2020 Oct; 29(10):1089-1098. PubMed ID: 32703039
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib in pyoderma gangrenosum - A case series.
Sathyanarayana VA; Roy D; Nagaraju B; Rao VKR
Int J Rheum Dis; 2024 Jan; 27(1):e14810. PubMed ID: 37395471
[TBL] [Abstract][Full Text] [Related]
9. Baricitinib Is First Approved COVID-19 Immunomodulatory Treatment.
Rubin R
JAMA; 2022 Jun; 327(23):2281. PubMed ID: 35727290
[No Abstract] [Full Text] [Related]
10. Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway.
Fitton J; Melville AR; Emery P; Nam JL; Buch MH
Rheumatology (Oxford); 2021 Sep; 60(9):4048-4054. PubMed ID: 33331938
[TBL] [Abstract][Full Text] [Related]
11. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study.
Le Voyer T; Gitiaux C; Authier FJ; Bodemer C; Melki I; Quartier P; Aeschlimann F; Isapof A; Herbeuval JP; Bondet V; Charuel JL; Frémond ML; Duffy D; Rodero MP; Bader-Meunier B
Rheumatology (Oxford); 2021 Dec; 60(12):5801-5808. PubMed ID: 33576769
[TBL] [Abstract][Full Text] [Related]
12. Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function.
Parra-Izquierdo I; Melrose AR; Pang J; Lakshmanan HHS; Reitsma SE; Vavilapalli SH; Larson MK; Shatzel JJ; McCarty OJT; Aslan JE
Platelets; 2022 Apr; 33(3):404-415. PubMed ID: 34097573
[TBL] [Abstract][Full Text] [Related]
13. A novel treatment for psoriatic arthritis: Janus kinase inhibitors.
Chen M; Dai SM
Chin Med J (Engl); 2020 Apr; 133(8):959-967. PubMed ID: 32209886
[TBL] [Abstract][Full Text] [Related]
14. [Extensive ulcerations in children: The difficulty diagnosing pyoderma gangrenosum].
Ramli I; Rachadi H; Amarouch H; Rimani M; Senouci K; Benzekri L; Hassam B
Arch Pediatr; 2015 Jul; 22(7):753-5. PubMed ID: 26047747
[TBL] [Abstract][Full Text] [Related]
15. Treatment with Janus kinase inhibitors in juvenile dermatomyositis: A review of the literature.
Sener S; Cam V; Ozen S; Batu ED
Semin Arthritis Rheum; 2024 Jun; 66():152426. PubMed ID: 38442462
[TBL] [Abstract][Full Text] [Related]
16. The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia.
Luschnig P; Kienzl M; Roula D; Pilic J; Atallah R; Heinemann A; Sturm EM
Biochem Pharmacol; 2021 Oct; 192():114690. PubMed ID: 34274356
[TBL] [Abstract][Full Text] [Related]
17. JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis.
Chen CX; Wang JJ; Li H; Yuan LT; Gale RP; Liang Y
Leukemia; 2021 Sep; 35(9):2616-2620. PubMed ID: 33990684
[TBL] [Abstract][Full Text] [Related]
18. Baricitinib in Alopecia Areata.
Messenger A; Harries M
N Engl J Med; 2022 May; 386(18):1751-1752. PubMed ID: 35507486
[No Abstract] [Full Text] [Related]
19. Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.
Miyazaki Y; Nakano K; Nakayamada S; Kubo S; Inoue Y; Fujino Y; Tanaka Y
Ann Rheum Dis; 2021 Sep; 80(9):1130-1136. PubMed ID: 33827788
[TBL] [Abstract][Full Text] [Related]
20. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
Taylor PC; Takeuchi T; Burmester GR; Durez P; Smolen JS; Deberdt W; Issa M; Terres JR; Bello N; Winthrop KL
Ann Rheum Dis; 2022 Mar; 81(3):335-343. PubMed ID: 34706874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]